Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Hippo Pathway Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for WWTR1/TAZ drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | WWTR1 (TAZ) Recombinant Protein (WT & TAZ S89A Mutant) High purity (>95%), Endotoxin controlled. Sequence Verified by Mass Spectrometry. |
View WWTR1 Products |
| Gene Delivery | WWTR1 Promise-ORF / Lentiviral Particles Full-length ORF and S89A constitutively active mutant for stable cell line generation. |
View WWTR1 Products |
| Benchmark Ab | Anti-WWTR1/TAZ Recombinant Antibody High-affinity positive control for Western Blot, IHC, and IP assays. |
View WWTR1 Products |
| Validator | WWTR1 siRNA Set Target-specific knockdown validation in cell-based functional assays. |
View WWTR1 Products |
| Related Target A | YAP1 Primary Hippo pathway coactivator sharing redundant functional roles and downstream TEAD binding partners. |
View YAP1 Products |
| Related Target B | TEAD1 Core transcription factor partner required for WWTR1/TAZ-mediated oncogenic gene expression. |
View TEAD1 Products |
| Related Target C | TEAD4 Key downstream effector of the Hippo pathway frequently co-targeted in YAP/TAZ-driven cancers. |
View TEAD4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| YAP/TAZ-TEAD Interaction Screening | High-purity WWTR1 and TEAD1/4 recombinant proteins with precise tag configurations (GST/His) for robust AlphaLISA/TR-FRET assays. |
| Nuclear Translocation Tracking | WWTR1-GFP Lentiviral particles for real-time high-content screening (HCS) of nuclear-cytoplasmic shuttling. |
| Phosphorylation-Independent Validation | Constitutively active TAZ S89A mutant proteins and lentivirus to bypass upstream LATS1/2 kinase regulation. |
| Lack of Validated Controls | Sequence-verified clinical benchmark antibodies and validated siRNA sets included for target specificity verification. |
Live WWTR1/TAZ R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The Hippo signaling pathway, particularly the transcriptional coactivator WWTR1 (TAZ) and its paralog YAP1, has emerged as a high-value node in oncology and regenerative medicine. Because WWTR1/TAZ lacks a direct small-molecule binding pocket, drug discovery has shifted from direct inhibition to targeting the WWTR1/TAZ-TEAD protein-protein interaction (PPI), upstream regulators (such as LATS1/2 and MST1/2), and downstream transcriptional complexes.
The race for WWTR1/TAZ therapeutics is intensifying, with major players shifting focus from traditional systemic cytotoxic agents to TEAD palmitoylation inhibitors and TAZ/YAP-TEAD interface disruptors. As first-generation therapies reach the clinic, the next wave of R&D is targeting drug-resistant phenotypes—particularly in EGFR-mutant NSCLC, KRAS-mutant colorectal cancer, and NF2-deficient mesothelioma where WWTR1/TAZ activation serves as a primary bypass resistance mechanism.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (TEAD Palmitoylation Inhibitor) | Vivace Therapeutics, Ikena Oncology, SpringWorks Therapeutics | NF2-deficient Mesothelioma, Schwannoma, Solid Tumors | Biophysical binding assays requiring high-purity TEAD and WWTR1/TAZ proteins. |
| Small Molecule (YAP/TAZ-TEAD PPI Disrupter) | Boehringer Ingelheim, Novartis, Inventiva | NSCLC, Hepatocellular Carcinoma, Fibrosis | In vitro TR-FRET/AlphaLISA assays utilizing GST-tagged WWTR1 and His-tagged TEAD. |
| PROTAC / Degrader | Targeted Protein Degradation Startups | Therapy-resistant Solid Tumors | Ubiquitination and degradation assays requiring stable cell lines generated via Lentiviral transduction. |